GN-HEARING
3.5.2021 09:02:09 CEST | Business Wire | Press release
GN Hearing, the global leader in hearing aid innovation, today unveils Interton Move , the newest addition to its leading portfolio of hearing solutions that caters to all user needs. Interton Move makes great sound quality and best-in-class connectivity more accessible, helping hearing care professionals meet the diverse needs of people living with hearing loss.
The lineup of 10 essential hearing aids represents the biggest upgrade in the history of Interton. People from across the hearing loss spectrum can now get more out of life with greater choice than ever before. Most importantly, people can now feel confident when communicating with friends and family as they can focus on what they want to hear. They benefit from improved listening comfort in different environments, made possible thanks to a new, faster, more powerful sound processing platform. The launch also presents new rechargeability options and full smartphone support with direct audio streaming and an app for personalization. These vital elements result in high-quality, yet affordable hearing care with all the benefits of GN’s leading and proven technology.
Globally, 430 million people live with hearing loss and only 1 in 5 people who could benefit from hearing aids actually use them.1 Untreated hearing loss has wide-reaching impacts on a person’s quality of life and happiness. As hearing loss can be perceived by some as a small problem and something to ignore or put up with, hearing aids may be seen as an overwhelming solution. With the new Interton Move portfolio, hearing care professionals can now offer simple and straightforward hearing care to more people than ever before.
GN Hearing CEO and President, Gitte Aabo, explains: “At GN Hearing, we want to make life sound better for every person with hearing loss. Treating hearing loss can radically transform an individual’s life, as they can hear more and return to doing what they love. With the launch of Interton Move, we’re pleased to support the crucial role that hearing care professionals play in helping people access the hearing care they need.”
The extensive portfolio includes a mini rechargeable Receiver-in-Ear (RIE), a mini Behind-the-Ear (BTE), custom hearing aids, and even a ‘Super Power’ option for profound hearing loss. The rechargeable RIE model and its matching desktop charger provide freedom from batteries and up to 30 hours of use on a single charge.
All Interton Move users can enjoy high-quality streaming of calls, music, and other audio directly from compatible Apple and AndroidTM devices. Meanwhile, the Interton Sound smartphone app enables users to personalize their hearing experience and connect to GN’s extensive range of wireless accessories.
All aspects of the fitting and onboarding process have been upgraded to improve the user experience and to ensure that the start of a person’s hearing journey is as seamless as possible. To make consulting easier for hearing care professionals, the Interton Fitting Software follows the same workflow as all other GN Hearing solutions.
Interton Move will roll out globally and be available in the first countries from May 2021.
NOTES TO EDITORS
About Interton
Interton was founded in Germany in 1962 and is part of the GN Group. Interton hearing aids are designed in Denmark and powered by pioneering technology that has transformed the sound quality, functionality, and comfort of hearing aids.
Visit our homepage interton.com – and connect with us on Facebook.
About GN Group
The GN Group enables people to Hear More, Do More and Be More through its intelligent hearing, audio and video collaboration solutions. Inspired by people and driven by our innovation leadership, we leverage technological synergies between our hearing and audio divisions to deliver unique and increasingly individualized user experiences in our products and solutions.
150 years ago, GN was founded with a truly innovative and global mindset. Today, we honor that legacy with world-leading expertise in the human ear, sound and video processing, wireless technology, miniaturization and collaborations with leading technology partners. GN's solutions are marketed by the brands ReSound, Beltone, Interton, Jabra, BlueParrott and FalCom in 100 countries. Founded in 1869, the GN Group employs 6,500 people and is listed on Nasdaq Copenhagen (GN.CO).
Visit our homepage GN.com and connect with us on LinkedIn and Facebook .
© 2021 GN Hearing A/S. All rights reserved. Interton is a trademark of GN Hearing A/S. Apple, the Apple logo, iPhone, iPad and iPod touch are trademarks of Apple Inc., registered in the U.S. and other countries. Android is a trademark of Google LLC.
1 WHO: Deafness and hearing loss: https://www.who.int/news-room/fact-sheets/detail/deafness-and-hearing-loss . Accessed on April 12, 2021. |
View source version on businesswire.com: https://www.businesswire.com/news/home/20210503005229/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Kubota Vision Inc. Signs Supply and Licensing Agreement with Laboratoires KÔL for Stargardt Disease Treatment Candidate Under Compassionate Use4.5.2026 17:16:00 CEST | Press release
Kubota Vision Inc. (“Kubota Vision”), a wholly-owned subsidiary of Kubota Pharmaceutical Holdings Co., Ltd. (Minato-ku, Tokyo, Japan) announced signing of a Supply and Licensing Agreement with Laboratoires KÔL (Clermont-Ferrand, France) for the provision of a Stargardt disease (STGD1) treatment candidate under compassionate use authorization. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260414590785/en/ The purpose of this Agreement is for Kubota Vision and KÔL to collaborate on providing “Emixustat” for treatment of Stargardt Disease (STGD1) through compassionate use authorization in France. Kubota Vision will exclusively manufacture and supply Emixustat final products to KÔL and KÔL will have exclusive rights to distribute Emixustat in France under compassionate use access. Ryo Kubota, Chairman, President, and CEO of Kubota Pharmaceutical Holdings, stated, “We are extremely pleased to enter into this Agreement with Labor
Incentive Market Set to Surpass $80B by 2030s — IMA Launches Tools to Help the Industry Keep Pace4.5.2026 16:28:00 CEST | Press release
With combined business spend on loyalty, employee recognition, and channel incentives projected to exceed $80 billion by the 2030s, the incentive industry is entering a period of rapid scale and strategic pressure. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260422729016/en/ In response, the Incentive Marketing Association (IMA) launched a new suite of resources designed to help incentive professionals navigate an environment that’s becoming more specialized, fragmented, and central to business performance. “It’s not just more money coming in—it’s more complexity,” said Vince Chiofolo, President of the Incentive & Engagement Solution Providers (IESP). “Buyers are demanding programs that evolve fast, integrate deeply, and feel personal at scale. These new tools were built for that.” IMA’s Suite of Tools Includes: New Industry Report — Inside the Incentive Buyer’s Mind Drawn from insights of 50+ program owners, the report f
Tigo Energy Breaks Global Growth Benchmark; Boosts U.S. Energy Feature in Predict+4.5.2026 15:00:00 CEST | Press release
Advanced energy prediction platform adds real-time energy pricing for North American Independent System Operator (ISO) customers, accelerates meters-connected growth. Tigo Energy, Inc. (NASDAQ: TYGO) (“Tigo” or “Company”), a leading provider of intelligent solar and energy solutions, today announced that the Predict+ platform now offers integrated real-time spot market pricing for ISO customers in the United States. Predict+ provides utilities with deep insights into grid demand, renewable generation, and energy market dynamics, enhancing the precision, scalability, and robustness of energy forecasting to up to 97.5% accuracy through machine learning and artificial intelligence. For energy providers, Predict+ helps streamline operations, reduce volatility, and maximize performance. Predict+ empowers utility operators to adapt to real-world demand challenges when balancing renewable and baseload generation sources, particularly during extreme weather events and market disruptions. On th
Airship Announces 2026 Elevate Customer Experience Award Winners4.5.2026 15:00:00 CEST | Press release
Southwest Airlines, The Economist, and OneFootball among brands recognized at Elevate’26 Customer Experience Summit for setting the standard in mobile-first and AI-centered customer experiences Airship, the mobile-first customer experience company, today announced the winners of the 2026 Elevate Customer Experience Awards. Global brand leaders from The Economist, Southwest Airlines, and OneFootball were among those honored at the Elevate’26 Customer Experience Summit. The Elevate Awards spotlight global companies that have developed exceptional mobile-first customer experiences for their customers, created innovative campaigns, leveraged AI agents to reach new levels of productivity, and achieved real business results. "Evolving mobile-first consumer behaviors and unprecedented advancements in AI are driving a seismic shift that is reshaping how brands interact with their customers," said Brett Caine, CEO, Airship. "The 2026 Elevate Award winners aren’t just adapting, they’re leading t
Alnylam to Present New Analyses at Heart Failure 2026 Underscoring Consistent Clinical Profile of Vutrisiran in ATTR-CM4.5.2026 14:30:00 CEST | Press release
Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced it will present new data analyses for vutrisiran in patients with the cardiomyopathy of wild-type or hereditary transthyretin-mediated amyloidosis (ATTR-CM) at Heart Failure 2026, a scientific congress of the European Society of Cardiology, taking place May 9-12, 2026, in Barcelona, Spain. ATTR-CM is a heterogeneous and rapidly progressive disease, and patients often present with complex clinical profiles. At Heart Failure 2026, Alnylam will present multiple new analyses from the Phase 3 HELIOS-B study of vutrisiran, which continue to support its use as a first-line treatment for patients with ATTR-CM, and further characterize its clinical profile across patients with a high disease burden, and in the context of concomitant therapies. Vutrisiran is the first and only transthyretin (TTR) silencer for ATTR-CM that delivers rapid knockdown of TTR at the source. Additional analyses being pr
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom